Howard A. Burris
Sarah Cannon · 1,136 works · 72,205 citations · h-index 117
Top works
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
- Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- Phase I and pharmacokinetic trial of weekly CPT-11.
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma
- Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas